|Novel Therapies in Phase 2b or Later for Symptomatic Treatment of the Underlying Symptoms of Schizophrenia with Special Emphasis on Treatment of Cognitive Impairment and Negative Symptoms.||Biomarkers and Integrated Solutions|
Collaborating in more than 150 countries.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.
Europe, Middle East & Africa (EMEA)
Focus on Schizophrenia Research
Our Areas of Interest for Collaboration